MAMaria Taís de Moura Fontes Araújo

Maria Taís de Moura Fontes Araújo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Taís de Moura Fontes Araújo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pharmacological Activities of the Genus Passiflora (Passifloraceae): A Patent Review

    by Ana Ediléia Barbosa Pereira Leal, Érica Martins de Lavor, Jackson de Menezes Barbosa, Maria Taís de Moura Fontes Araújo, Cristiane dos Santos Cerqueira Alves, Raimundo Gonçalves de Oliveira Júnior, Ádley Antonini Neves de Lima, Jackson Roberto Guedes da Silva Almeida

    Background: Passiflora L. is a genus belonging to the Passifloraceae family, with many species widely used in folk medicine and several pharmacological activities described in the scien-tific literature, being a major target for the development of new therapeutic products. Studies have identified several bioactive compounds in their composition as responsible for these activities, mainly C-glycoside flavonoids. Objective: The aim of this study was to carry out a review of patents related to the genus and its ap-plication in several pharmacological activities, important for the development of new drugs and formulations. Method: The search was carried out in 5 specialized databases, INPI, EPO, WIPO, Latipat and Derwent, using the term ‘Passiflora’ combined with ‘A61K and A61P', subclasses of section A of the International Patent Classification (IPC), which are destined to medical, dental or hygienic pur-poses, and therapeutic activity of chemical compounds or medicinal preparation, respectively. Results: 1,198 patents citing the genus in the title or abstract have been found, 508 being duplicates. After exclusion and inclusion criteria, 23 patents written in English, Portuguese and Spanish were selected, which demonstrated biological assays in vivo with species of Passiflora as the only active constituent or incorporated in formulations with other compounds. Conclusion: The findings of this search showed growing interest in research and industrial areas in the pharmaceutical development with species of Passiflora, suggesting that the different bioactive compounds present in the genus can be considered as an important tool for the development of new effective and safe products with pharmacological potential.